Kezar Life Sciences Aktie (A2JPE7

Was macht Kezar Life Sciences?

Unternehmensprofil

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Chart der Kezar Life Sciences Aktie

Charttool öffnen

Aktuelle Nachrichten zu Kezar Life Sciences

Weitere Nachrichten

Das berichten andere über Kezar Life Sciences

Kezar Life Sciences (KZR) Upgraded to Buy: Heres What You Should Know

Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Kezar Life Sciences announces workforce reduction as part of restructuring By Investing.com

Kezar Life Sciences announces workforce reduction as part of restructuring

Kezar Life Sciences stock gains after FDA lifts partial clinical hold By Investing.com

Kezar Life Sciences stock gains after FDA lifts partial clinical hold

Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?

Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects. This might drive the stock higher...